Hypertension
Conditions
Brief summary
The purpose of this study is to research the effects of partial sleep deprivation (sleep restriction) in a group of individuals whose parents have high blood pressure compared to a group of individuals whose parents have normal blood pressure.
Interventions
BEHAVIORALPartial sleep deprivation (sleep restriction)
During the experimental segment the sleep opportunity will be restricted to 5 hours/night. During the acclimation and recovery phases a 9-hour/night sleep opportunity will be provided.
BEHAVIORALNormal sleep
During the normal sleep condition a 9-hour/night sleep opportunity will be provided throughout the 10-day inpatient visit.
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
Mayo Clinic
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adults aged 18-35 years * Absence of any significant medical or psychiatric disease (as per the investigators' judgment) * Nonsmoker * Nonpregnant * History of normal sleep duration (reported average sleep duration between 7-9 hours/night and no habitual napping) * Hypertension status information available for both biological parents * Ability to understand study procedures and to comply with them for the entire length of the study * Ability to understand English and provide informed consent
Exclusion criteria
* Age \<18 or \>35 years * Body mass index \<18.5 or ≥30 kg/m2 * Pregnant or lactating * Unable to determine history of HTN in participant's biological parents or subject being adopted * Use of tobacco, vaping, marijuana products or other drugs * Excessive caffeine consumption (\>400 mg/day) * Excessive alcohol consumption (\>7 drinks/week for women, \>14 drinks/week for men) * Office SBP/DBP ≥130/80 mmHg * Daytime ambulatory SBP/DBP ≥130/80 mmHg * Fasting glucose ≥126 mg/dl * Glomerular filtration rate \<60 mL/min/BSA * History of significant medical or psychiatric disorders (as per the investigators' judgment) * Regular use of prescription medications other than contraceptives * Use of melatonin supplements or any other over-the-counter sleep aid * Moderate-to-severe sleep disordered breathing (apnea/hypopnea index, AHI ≥15) or mild sleep disordered breathing (AHI 5-15) with daytime sleepiness (Epworth Sleepiness Scale \>10) * Moderate-to-severe insomnia (Insomnia Severity Index \>14) * Restless leg syndrome (as per the Cambridge-Hopkins questionnaire) * Excessive daytime sleepiness (Epworth Sleepiness Scale \>15) * Extreme chronotype (Morningness-Eveningness Questionnaire \>69 or \<31) * Night shift work * Ongoing participation in other research studies (as per the investigators' judgment) * Any other medical, geographic, or social factor making study participation impractical * Not English-speaking and/or inability to provide informed consent * Exclusionary for blood draws: hemoglobin \<11.6 g/dL in women / \<13.2 g/dL in men; participants with measured hemoglobin levels below these thresholds will be allowed to continue participate in study tests and procedures not involving blood draws.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 24-hour Systolic Blood Pressure (BP) | Day 2, Day 4, Day 7, and Day 9 | Systolic Blood pressure will be measured in mmHg |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 24-hour Diastolic blood pressure (DBP) | Day 2, Day 4, Day 7, and Day 9 | Diastolic blood pressure will be measured in mmHg |
| Awake Systolic Blood Pressure/Diastolic Blood Pressure (SBP/DBP) | Day 2, Day 4, Day 7, and Day 9 | Awake SBP/DBP will be measured in mmHg/mmHg |
| Asleep Systolic Blood Pressure/Diastolic Blood Pressure (SBP/DBP) | Day 2, Day 4, Day 7, and Day 9 | Asleep SBP/DBP will be measured in mmHg/mmHg |
| Systolic Blood Pressure/Diastolic Blood Pressure (SBP/DBP) Nocturnal dipping | Day 2, Day 4, Day 7, and Day 9 | SBP/DBP Nocturnal dipping will be measured in percent (%) |
| Catecholamines | Day 2, Day 4, Day 7, and Day 9 | Catecholamines will be measured from a 24-hour urine collection. |
| Endothelial Function | Day 3, Day 5, Day 8, and Day 10 | Endothelial function will be estimated from flow-mediated vasodilation using ultrasound. |
| Blood Pressure (BP) response to stressors | Day 3, Day 5, Day 8, and Day 10 | BP response to stressors will be measured in mmHg |
| Heart Rate response to stressors | Day 3, Day 5, Day 8, and Day 10 | Heart Rate response to stressors will be measured by ECG |
| DNA-methylation | Day 3, Day 5, Day 8, and Day 10 | Methylated gene markers in peripheral blood mononuclear cells will be obtained |
| Transcriptomic | Day 3, Day 5, Day 8, and Day 10 | Whole transcriptome in peripheral blood mononuclear cells will be obtained |
| Baroreflex Sensitivity | Day 3, Day 5, Day 8, and Day 10 | Baroreflex Sensitivity will be measured from simultaneous electrocardiography (ECG) and noninvasive beat-to-beat BP recording. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Arterial Tonometry | Day 3, Day 5, Day 8, and Day 10 | Pulse wave velocity will be measured by Applanation tonometry |
Countries
United States
Contacts
Primary ContactSabah Munir
Outcome results
None listed